Dyadic Logo Current.jpg
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
October 04, 2022 08:45 ET | Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
August 10, 2022 16:00 ET | Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Dyadic Logo Current.jpg
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET | Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Dyadic Logo Current.jpg
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
April 13, 2022 08:52 ET | Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
Dyadic Logo Current.jpg
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
December 17, 2021 07:00 ET | Dyadic International, Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Logo Current.jpg
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
August 11, 2021 08:35 ET | Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
Dyadic Logo Current.jpg
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
July 27, 2021 08:20 ET | Dyadic International, Inc.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III...
Dyadic Logo Current.jpg
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
June 28, 2021 08:30 ET | Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
PDF to PNG Logo.png
MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
August 19, 2020 12:59 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta”) (NASDAQ GS: MNTA) regarding possible...
Aleafia Health - Science Seeding Wellness
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
July 24, 2020 07:15 ET | Aleafia Health Inc.
SPRAVATO® (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder Aleafia Health medical clinics along with select physicians and...